文献速递类风湿关节炎

合并症预测早期类风湿关节炎患者尽管接受强化治疗仍预后更差:CareRA试验的事后评估

Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于为期2年的实用随机对照CareRA试验,纳入379例早期RA患者,量化基线合并症患病率并分析其对疗效结局的预后价值。结果显示44%患者至少有一种合并症,合并症与更高的HAQ、DAS28-CRP及更低的SF-36躯体成分评分相关,且缓解机会更低、住院风险更高。

要点

  • 早期RA患者中44%至少有一种临床重要合并症,高血压最常见(22%)。
  • 合并症与2年内更差的身体功能、疾病活动度和生活质量独立相关。
  • 合并症患者缓解机会更低(OR=0.724),住院风险更高(OR=3.725)。

核心结论

  • 在早期RA发病时,近半数患者至少有一种临床重要合并症;合并症与2年内更差的功能和疾病活动度结局相关,尽管接受了强化缓解诱导治疗。

研究设计与样本

  • 研究为2年实用随机对照CareRA试验的事后评估,纳入379例早期RA(诊断<1年)、未使用过DMARD且以达标治疗为目标的患者,基线登记合并症并计算RDCI(范围0-9)。

主要发现

  • 379例患者中167例(44%)RDCI≥1;RDCI为1、2、≥3者分别有65例(17%)、70例(19%)、32例(8%);最常见合并症为高血压(22%)。
  • 校正包括疾病活动和随机治疗在内的混杂因素后,有合并症者2年内HAQ更高(β=0.215;95%CI:0.071,0.358)、DAS28-CRP更高(β=0.225;95%CI:0.132,0.319)、SF-36躯体成分汇总评分更低(β=-3.195;95%CI:-4.844,-1.546)。
  • 有合并症者随时间推移达到缓解的机会更低(OR=0.724;95%CI:0.604,0.867),住院风险更高(OR=3.725;95%CI:2.136,6.494)。

临床怎么用

  • 对早期RA患者应评估基线合并症(如高血压),合并症负担重者即使接受强化达标治疗也可能功能与疾病活动度结局更差、缓解率更低且住院风险更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To quantify the prevalence of co-morbidities in patients with early RA and determine their prognostic value for effectiveness outcomes in a randomized trial. METHODS: We included patients from the 2-year pragmatic randomized CareRA trial, who had early RA (diagnosis < 1 year), were DMARD naïve and then treated-to-target with different remission induction schemes. Prevalence of co-morbidities was registered at baseline and the Rheumatic Diseases Comorbidity Index (RDCI; range 0-9) was calculated. We tested the relation between baseline RDCI and outcomes including disease activity (DAS28-CRP), physical function (HAQ index), quality of life (SF-36 domains) and hospitalizations over 2 years, using linear mixed models or generalized estimating equations models. RESULTS: Of 379 included patients, 167 (44%) had a RDCI of minimum 1. RDCI scores of 1, 2 or ≥3 were obtained in 65 (17%), 70 (19%), and 32 (8%) participants, respectively. The most frequent co-morbidity was hypertension (22%). Patients with co-morbidities had significantly higher HAQ (β = 0.215; 95% CI: 0.071, 0.358), DAS28-CRP (β = 0.225; 95% CI: 0.132, 0.319) and lower SF-36 physical component summary scores (β =-3.195; 95% CI: -4.844, -1.546) over 2 years than patients without co-morbidities, after adjusting for possible confounders including disease activity and randomized treatment. Patients with co-morbidities had over time lower chances of achieving remission (OR = 0.724; 95% CI: 0.604, 0.867) and a higher risk of hospitalization (OR = 3.725; 95% CI: 2.136, 6.494). CONCLUSION: At disease onset, almost half of RA patients had at least one clinically important co-morbidity. Having co-morbidities was associated with worse functionality and disease activity outcomes over 2 years, despite intensive remission induction treatment. TRIAL REGISTRATION: Clinical trials NCT01172639.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Stouten V, Westhovens R, De Cock D, et al. Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial. Rheumatology (Oxford). 2021. PMID: 33434277. doi:10.1093/rheumatology/keaa841

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。